Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
46
resultados
Última actualización
02/08/2026 [06:45:00]
Resumen de: US20260215689A1
0000 Smart glasses have an outward side and an inward side facing a user. A light source is attached to the outward side emits a light beam. One or more cameras are attached to the outward side to capture images or videos. The smart glasses include a processor, speakers, and one or more microphones that receive voice control or interactions. The smart glasses are coupled to a non-transitory computer readable medium and a smart phone or a tablet. The smart glasses interact with a multi-modal generative artificial intelligence assistant including a transformer with self-attention and position encoding layers that performs computer vision and natural language processing. The glasses may also have displays, touch sensors, memory, machine learning and gesture analysis, and the ability to recognize an object. The glasses may also be coupled to a wearable device with contact-based sensors.
Resumen de: US20260217758A1
0000 Disclosed herein are polypeptides comprising an extended recombinant polypeptide (XTEN) comprised of a plurality of overlapping sequence motifs and one or more barcode fragments releasable upon protease digestion and detectable from all other proteolytically releasable fragments. Certain embodiments of these polypeptides further comprise a biologically active polypeptide, wherein advantageous embodiments thereof comprise a releasable segment capable of proteolytic cleavage that cleaves the linkage between the XTEN polypeptide and the biologically active polypeptide. Methods of making and methods of using said polypeptides are also disclosed.
Resumen de: US20260219277A1
The present invention relates to a fluorescent compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof; and a composition for detecting gingipain, composition for diagnosing Porphyromonas gingivalis (P. gingivalis) infection or antibacterial composition against P. gingivalis using the same:
Resumen de: US20260216327A1
0000 Provided are adoptive cell therapy involving the administration of doses of cells for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a large B cell lymphoma, such as a diffuse large B-cell lymphoma (DLBCL). Also provided are methods of assessing the risk of developing a toxicity related to a cell therapy, and methods of identifying subjects and methods of treating subjects based on the assessment of risks.
Resumen de: US20260218203A1
The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′ SEQ. ID. NO: 27, wherein Xu is U or absent.
Resumen de: US20260216227A1
The present disclosure provides method of preventing, lessening the effects, or treating cytokine release syndrome (CRS) or related disorders, and/or neurotoxicity associated with immunotherapy comprising administering defibrotide. The defibrotide can be administered after the immunotherapy begins or be administered prophylactically before immunotherapy begins or before the patient develops CRS and/or neurotoxicity.
Resumen de: US20260216274A1
A method of treating a patient with moderate-to-severee traumatic brain injury (TBI) undergoing emergency craniotomy includes administering, in addition to orthodox therapy (OT), intravenous Xingnaojing (XNJ) for seven consecutive days in an intensive care setting, wherein acute postoperative neurological recovery is improved as measured by Glasgow Coma Scale (GCS) during postoperative Days 1, 3, 5, and 7, wherein long-term functional outcome is improved as measured by Glasgow Outcome Scale (GOS) and Karnofsky Performance Status (KPS) at 30 and 90 days, and wherein secondary-injury biomarkers are modulated by reducing serum S100B and preserving or restoring serum superoxide dismutase (SOD) activity relative to OT alone.
Resumen de: US20260219284A1
Methods, compositions and kits useful in the detection, assessment, diagnosis, prognosis and/or treatment of brain injuries, especially mild traumatic brain injury (mTBI) or concussion, are based upon detection of changes in levels of certain protein biomarkers in a subject undergoing testing, or upon detection of changes in levels of certain protein biomarkers in conjunction with neuroimaging analyses to detect changes in vascular or blood brain barrier (BBB) permeability in the brain, or to detect damage to fiber tracts in the brain, in which changes in biomarker levels correlate with detection of changes in BBB permeability or in brain fiber tract or white matter damage in a subject with brain injury such as mTBI or concussion.
Resumen de: US20260217847A1
The present invention provides an anti-TfR1 single-domain antibody and a use thereof. The single-domain antibody includes a heavy chain variable region, wherein the heavy chain variable region includes a heavy chain CDR1 as shown in any one of SEQ ID NO: 53-SEQ ID NO: 60, a heavy chain CDR2 as shown in any one of SEQ ID NO: 61-SEQ ID NO: 72, and a heavy chain CDR3 as shown in any one of SEQ ID NO: 73-SEQ ID NO: 82.
Resumen de: US20260219283A1
0000 Synucleinopathies are a group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These diseases are characterized by the aggregation and deposition of α-synuclein (α-syn) in Lewy bodies (LBs) in PD and DLB or as glial cytoplasmic inclusions in MSA. In healthy brains, only ~4% of α-syn is phosphorylated at Ser129 (pS129-α-syn), whereas >90% pS129-α-syn may be found in LBs. Embodiments of the invention include a duplex assay for both total α-synuclein and pS129-α-synuclein, which allows measuring both analytes in the same sample, leading to substantial saving in sample volume. The assays can be widely used in methods for detecting pS129-α-syn in biomedical studies including when only a limited volume of sample is available and high sensitivity is required, offering new opportunities for diagnostic biomarkers, monitoring disease progression, and quantifying outcome measures in clinical trials.
Resumen de: US20260217667A1
Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the methods for treating of diseases associated with an amyloid or amyloid like proteins.
Resumen de: US20260217804A1
Disclosed is an antibody or antigen-binding fragment thereof, which binds to AβpE3, i.e. to an N-terminally truncated and pyroglutamate-modified form of amyloid beta (Aβ), and therapeutic and diagnostic uses thereof.
Resumen de: US20260219265A1
0000 Described is a method and device for detecting an analyte in a sample, comprising bringing a sample comprising a target analyte into contact with magnetisable particles, the particles being coated with binding molecules complementary to the target analyte, resulting in bound and unbound binder complexes, positioning the magnetisable particles, comprising both bound and unbound binder complexes, in proximity to a magnetic field sensor, changing the magnetic field sufficient to release at least a portion of the magnetisable particles, comprising both bound and unbound binder complexes, from their proximity to the magnetic field sensor, and measuring changes in a magnetic signal detected from the net movement, being either translational or rotational movement, of the magnetisable particles relative to the magnetic sensor.
Resumen de: EP4781999A1
0001 The present invention relates to Engrailed protein, a nucleic acid encoding Engrailed protein and compositions comprising the same for use in treating or preventing diseases associated with accumulation of TDP-43 in the cell, particularly in the cell cytoplasm. Also provided herein are in vitro methods of selecting a subject for such therapy by detecting cellular accumulation of TDP-43, particularly cellular cytoplasmic accumulation, in a biological sample of the subject. Also provided herein are in vitro methods of following a subject treated with such therapy by measuring cellular accumulation, particularly cellular cytoplasmic accumulation, of TDP-43 in a biological sample of the treated subject.
Resumen de: WO2025064229A1
The disclosure pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, the disclosure describes methods of assaying a sample obtained from a subject having or suspected of having a cognitive impairment for one or more proteins selected from: DLL1, VNN2, VAV3, and SUMF1. In certain embodiments, the cognitive impairment is caused by a neurodegenerative disease, such as Alzheimer's disease. The methods further comprise identifying a subject as likely or not likely to respond positively to the plasma exchange therapy. In even further aspects, the disclosure describes methods for treating a cognitive impairment in the subject by a plasma exchange therapy, wherein based on the specific protein expression data, the subject is identified as likely or not likely to respond positively to the plasma exchange therapy. The plasma exchange therapy can be full and/or low volume plasma exchange. Also provided are kits suitable for performing the methods disclosed herein.
Resumen de: WO2021127549A1
Disclosed herein are methods for making a transcriptome-wide expression profile of a biological sample and identifying biomarkers that can be used to diagnose, monitor the onset, monitor the progression, and assess the recovery of a disease in a subject. The biomarkers can also be used to establish and evaluate treatment regimens.
Resumen de: AU2025226972A1
The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.
Resumen de: WO2026156063A1
Provided are methods for diagnosing and treating schizophrenia based on the presence of biomarkers for schizophrenia. The biomarkers can comprise specificity protein 4 (SP4) mRNA and heat shock protein 60 (HSP60) protein.
Resumen de: US20260210980A1
The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.
Resumen de: US20260210903A1
0000 An organic electrolyte-gated field effect transistor biosensor contains a microfluidic channel structure formed from a dielectric thermoplastic material. A biorecognition entity immobilized within the microfluidic channel allows the biosensor to detect the presence or concentration of an analyte in an electrolyte fluid placed within the channel. The dielectric material separates the microfluidic channel from the gate electrode and from the semiconductor material connecting the drain and source electrodes, and protects the gate electrode and the semiconductor material from direct contact with the electrolyte fluid in the microfluidic channel, to provide the biosensor with a high capacitance. Methods of fabricating the biosensor by monolithic 3D printing are also provided.
Resumen de: AU2026205405A1
A method for operating a virtual assistant, the method comprising: at an electronic device: initiating a virtual assistant operable to connect a user with one or more repositories of health information; identifying, by the virtual assistant, the user based on one or more user-specific features; associating a subset of the health information with the user based on the identification of the user, at least a portion of the subset of the health information relating to a particular subject; responsive to receiving a user input via the virtual assistant: accessing, by the virtual assistant, the one or more repositories of information; identifying one or more documents within the one or more repositories as being relevant to the user input; extracting partial response data from the one or more documents; processing, by the virtual assistant, the partial response data in view of the user input to generate a complete response to the user input; and providing the complete response for broadcasting via an output device associated with the electronic device, wherein the steps of identifying one or more documents within the one or more repositories as being relevant to the user input and extracting partial response data from the one or more documents include: identifying at least one parameter in the user input; identifying at least one intent associated with the user input, the at least one intent selected from a pool of intents identified from a plurality of intents based on the at leas
Resumen de: US20260209718A1
0000 The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.
Resumen de: US20260209296A1
Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.
Resumen de: US20260210981A1
Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.
Nº publicación: US20260209322A1 23/07/2026
Solicitante:
HAMAD BIN KHALIFA UNIV [QA]
HAMAD BIN KHALIFA UNIVERSITY
Resumen de: US20260209322A1
0000 The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.
BOPI
Sede Electrónica
